Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 4.8% - Here's What Happened

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) shares were down 4.8% during mid-day trading on Monday . The stock traded as low as $6.44 and last traded at $6.55. Approximately 4,844,177 shares traded hands during trading, a decline of 68% from the average daily volume of 14,941,520 shares. The stock had previously closed at $6.88.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on RXRX. KeyCorp cut their price target on Recursion Pharmaceuticals from $12.00 to $10.00 and set an "overweight" rating for the company in a report on Wednesday, January 8th. Needham & Company LLC reiterated a "buy" rating and issued a $11.00 price objective on shares of Recursion Pharmaceuticals in a research report on Wednesday, December 11th. Three investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average price target of $8.75.

Recursion Pharmaceuticals Stock Performance

The company has a quick ratio of 4.35, a current ratio of 4.35 and a debt-to-equity ratio of 0.04. The company has a market cap of $2.63 billion, a PE ratio of -4.41 and a beta of 0.85. The company has a 50-day moving average of $6.94 and a 200-day moving average of $6.97.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($0.34) EPS for the quarter, missing the consensus estimate of ($0.33) by ($0.01). The firm had revenue of $26.08 million during the quarter, compared to analysts' expectations of $12.62 million. Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. Recursion Pharmaceuticals's revenue for the quarter was up 147.6% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.43) EPS. As a group, analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current year.

Insider Buying and Selling

In other Recursion Pharmaceuticals news, CFO Michael Secora sold 15,000 shares of Recursion Pharmaceuticals stock in a transaction dated Wednesday, November 13th. The shares were sold at an average price of $7.66, for a total value of $114,900.00. Following the completion of the transaction, the chief financial officer now directly owns 1,499,631 shares of the company's stock, valued at approximately $11,487,173.46. The trade was a 0.99 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Blake Borgeson sold 11,447 shares of the company's stock in a transaction on Tuesday, October 15th. The shares were sold at an average price of $6.67, for a total value of $76,351.49. Following the transaction, the director now directly owns 7,089,007 shares in the company, valued at approximately $47,283,676.69. The trade was a 0.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 55,341 shares of company stock worth $393,490 in the last ninety days. 15.75% of the stock is owned by insiders.

Institutional Trading of Recursion Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the stock. Allspring Global Investments Holdings LLC purchased a new position in shares of Recursion Pharmaceuticals during the third quarter worth approximately $25,000. GAMMA Investing LLC increased its holdings in shares of Recursion Pharmaceuticals by 1,979.2% during the fourth quarter. GAMMA Investing LLC now owns 5,198 shares of the company's stock valued at $35,000 after acquiring an additional 4,948 shares in the last quarter. Farther Finance Advisors LLC lifted its stake in shares of Recursion Pharmaceuticals by 176.9% during the third quarter. Farther Finance Advisors LLC now owns 6,404 shares of the company's stock worth $42,000 after buying an additional 4,091 shares during the period. KBC Group NV grew its stake in Recursion Pharmaceuticals by 79.9% during the 3rd quarter. KBC Group NV now owns 7,602 shares of the company's stock valued at $50,000 after purchasing an additional 3,377 shares during the last quarter. Finally, Amalgamated Bank increased its holdings in Recursion Pharmaceuticals by 52.4% in the 2nd quarter. Amalgamated Bank now owns 7,152 shares of the company's stock worth $54,000 after buying an additional 2,459 shares during the period. 89.06% of the stock is currently owned by institutional investors.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.